Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
Phase 2
Completed
- Conditions
- Covid19 Vaccine
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Providence Therapeutics Holdings Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT05175742
- Locations
- 🇨🇦
LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada
🇨🇦Malton Medical, Mississauga, Ontario, Canada
🇨🇦Red Maple, Ottawa, Ontario, Canada
PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
Phase 1
Completed
- Conditions
- Covid19 Vaccine
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Providence Therapeutics Holdings Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04765436
- Locations
- 🇨🇦
Manna Research, Toronto, Ontario, Canada
News
No news found